EUVIMEDEUVIMED entdecken
Crossref

Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer

Yue Wang iD, Xin Li, Shuang Zhang, Li Liang, Ling Xu, Yinhua Liu, Ting Li

Japanese Journal of Clinical Oncology · 2024

DOI: 10.1093/jjco/hyae072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Yue Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our aim was to compare the PIK3CA mutation status in matched primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) breast cancer (BC) to gain insight into the optimization of patient selection and detection time for PIK3CA-targeted therapy.

Methods

The data were from 3035 patients with BC diagnosed at the Breast Disease Center, Peking University First Hospital, between January 2008 and December 2017. Matched primary and recurrent samples were profiled using amplification-refractory mutation system-polymerase chain reaction covering 11 mutational hotspots in PIK3CA.

Results

PIK3CA mutations were detected in 54.3% primary tumors and 48.6% corresponding recurrences. PIK3CA mutation was detected in 37.5% cases in the locoregional recurrent group and 40.0% of distant metastasis, without a statistical difference. Besides, PIK3CA mutations were concordant in 88.6% of the matched pairs. For patients treated with neoadjuvant chemotherapy, 100% concordance was observed. However, PIK3CA mutation was neither correlated with clinicopathological features nor associated with clinical outcomes.

Conclusions

Mutations in PIK3CA in HR+/HER2− BC generally progressed to recurrent tumors. The high concordance rate of PIK3CA mutation status between primary tumors and corresponding recurrences suggests that the detection of primary tumors could be a substitute approach when recurrent samples are not easily obtainable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesMutationNeoplasm Recurrence, LocalReceptors, ProgesteroneReceptors, EstrogenHumansFemaleMiddle AgedAdultAgedBiomarkers, Tumor

Stichwörter der Autor:innen

HER2HRPIK3CAbreast cancerrecurrence

Substanzen

Class I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenBiomarkers, TumorPIK3CA protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Peking University First Hospital, Beijing 100034, China.
  • Breast Disease Center, Peking University First Hospital, Beijing 100034, China.

ORCID-Profile: Yue Wang

Zitieren

APA

Wang, Y., Li, X., Zhang, S., Liang, L., Xu, L., Liu, Y., & Li, T. (2024). Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae072

Vancouver

Wang Y, Li X, Zhang S, Liang L, Xu L, Liu Y, et al. Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae072

BibTeX
@article{Wang2024,
  author = {Wang, Yue and Li, Xin and Zhang, Shuang and Liang, Li and Xu, Ling and Liu, Yinhua and Li, Ting},
  title = {Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1093/jjco/hyae072}
}
Kostenlos starten →